James T Boyd
Overview
Explore the profile of James T Boyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oertel W, Muller H, Unger M, Schade-Brittinger C, Balthasar K, Articus K, et al.
NEJM Evid
. 2024 Feb;
2(9):EVIDoa2200311.
PMID: 38320207
BACKGROUND: Epidemiologic studies show that smokers have a lower incidence of Parkinson’s disease. Nicotine has been hypothesized to slow progression in early Parkinson’s disease. METHODS: In a double-blind, placebo-controlled multicenter...
2.
Hanna S, Palmadottir V, Penar P, Boyd J
Clin Park Relat Disord
. 2023 Jan;
8:100175.
PMID: 36594072
Neuropsychiatric adverse events have been previously reported following deep brain stimulation (DBS) for Parkinson's disease (PD). Most cases described have involved DBS of the subthalamic nucleus (STN). We report a...
3.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....
4.
Schwarzschild M, Ascherio A, Casaceli C, Curhan G, Fitzgerald R, Kamp C, et al.
JAMA
. 2021 Sep;
326(10):926-939.
PMID: 34519802
Importance: Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical...
5.
Boyd J, Zadikoff C, Benesh J, Zamudio J, Robieson W, Kukreja P, et al.
Clin Park Relat Disord
. 2021 Jul;
2:25-34.
PMID: 34316616
Introduction: As Parkinson's disease (PD) progresses, the number/frequency of PD medications tend to increase, which is correlated with decreased patient compliance and suboptimal control of PD symptoms. We investigated efficacy...
6.
Gupta D, Marano M, Zweber C, Boyd J, Kuo S
Tremor Other Hyperkinet Mov (N Y)
. 2021 Jan;
10:58.
PMID: 33384882
Background: Despite the significance of tremor in Parkinson's disease (PD) diagnosis, classification, and patient's quality of life, there is a relative lack of data on prevalence and relationship of different...
7.
Zadikoff C, Poewe W, Boyd J, Bergmann L, Ijacu H, Kukreja P, et al.
Parkinsons Dis
. 2020 Feb;
2020:9716317.
PMID: 32104560
Background: Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson's disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in...
8.
Quik M, Boyd J, Bordia T, Perez X
Nicotine Tob Res
. 2018 Aug;
21(3):357-369.
PMID: 30137517
Implications: Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine...
9.
Fernandez H, Boyd J, Fung V, Lew M, Rodriguez R, Slevin J, et al.
Mov Disord
. 2018 Mar;
33(6):928-936.
PMID: 29570853
Background: Levodopa-carbidopa intestinal gel (designated as carbidopa-levodopa enteral suspension in the United States) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease patients through continuous delivery...
10.
Standaert D, Boyd J, Odin P, Robieson W, Zamudio J, Chatamra K
NPJ Parkinsons Dis
. 2018 Feb;
4:4.
PMID: 29387783
Levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa enteral suspension in the United States) is a treatment option for advanced Parkinson's disease (PD) patients with motor fluctuations. The objective of this investigation was...